Samantha Morais1,2, Ana Rute Costa1, Luisa Lopes-Conceicao1, Mariana Brandao3, Marina Borges4,5, Natalia Araujo1, Teresa Dias4, Filipa Fontes1,2,4, Susana Pereira1,4, Nuno Lunet6,2. 1. EPIUnit - Instituto de Saúde Pública, University of Porto, Porto, Portugal. 2. Department of Forensic and Public Health Sciences and Medical Education, Faculty of Medicine, University of Porto, Porto, Portugal. 3. Academic Promoting Team - Institute Jules Bordet, Brussels, Belgium. 4. Instituto Português de Oncologia do Porto FG, EPE (IPO-Porto), Porto, Portugal. 5. National School of Public Health, Universidade Nova de Lisboa, Lisbon, Portugal. 6. EPIUnit - Instituto de Saúde Pública, University of Porto, Porto, Portugal nlunet@med.up.pt.
Abstract
BACKGROUND/AIM: To quantify the association between a previous cancer diagnosis and healthcare use among breast cancer (BC) patients, and estimate five-year recurrence-free survival (RFS). PATIENTS AND METHODS: Women with BC were classified according to a previous cancer diagnosis (BC or other). Healthcare use during the first year and five-year RFS were obtained through clinical and administrative records. Adjusted odds ratios and hazard ratios (HR) were estimated. RESULTS: Among 681 BC patients, 21 had a previous BC and 32 a previous non-BC. The latter were less likely to receive anthracycline-based combination chemotherapy. The former had higher odds of mastectomy and genetic testing. Five-year RFS HRs (95% confidence interval) were 2.75 (0.79-9.52) and 0.52 (0.07-3.89) for previous BC and non-BC, respectively. CONCLUSION: Previous cancer was associated with less anthracycline-based combination chemotherapy, and patients were more likely to undergo mastectomy and genetic testing. These findings highlight the need for assessment of previous treatments, personal genetic risk and current BC characteristics. Copyright
BACKGROUND/AIM: To quantify the association between a previous cancer diagnosis and healthcare use among breast cancer (BC) patients, and estimate five-year recurrence-free survival (RFS). PATIENTS AND METHODS: Women with BC were classified according to a previous cancer diagnosis (BC or other). Healthcare use during the first year and five-year RFS were obtained through clinical and administrative records. Adjusted odds ratios and hazard ratios (HR) were estimated. RESULTS: Among 681 BCpatients, 21 had a previous BC and 32 a previous non-BC. The latter were less likely to receive anthracycline-based combination chemotherapy. The former had higher odds of mastectomy and genetic testing. Five-year RFS HRs (95% confidence interval) were 2.75 (0.79-9.52) and 0.52 (0.07-3.89) for previous BC and non-BC, respectively. CONCLUSION: Previous cancer was associated with less anthracycline-based combination chemotherapy, and patients were more likely to undergo mastectomy and genetic testing. These findings highlight the need for assessment of previous treatments, personal genetic risk and current BC characteristics. Copyright